---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-078752"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T12:59:17.811815+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Sagimet Biosciences enters $75M ATM equity facility with Leerink Partners, terminates prior Cantor facility

## Summary
- Up to $75M in common stock may be sold from time to time via at-the-market offerings through Leerink Partners.
- Agent commission of up to 3.0% on gross proceeds from sales under the agreement.
- Prior Cantor Fitzgerald ATM agreement terminated effective Aug 14, 2025; no shares were sold under that facility.

## SEC filing metadata
- accession: 0001104659-25-078752
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465925078752/0001104659-25-078752-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465925078752/tm2523529d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-078752
- JSON: https://secwatch.observer/filing/0001104659-25-078752.json
- Plain text: https://secwatch.observer/filing/0001104659-25-078752.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.